Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Prevention of Postoperative Delirium in Brain Tumor Patients
NCT04399343Phase 4Unknown
- Sponsor
- Capital Medical University
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in postoperative delirium (POD) (2 arms), sponsored by Capital Medical University. Primary endpoint: The incidence of postoperative delirium. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on NCT04399343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04399343.